REGULATED INFORMATION

GHENT, Belgium, 24 January 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Van Herk Investments B.V.

The above shareholder notified Ablynx that it has exceeded the 10% threshold on 19 January 2017 and now holds 6,148,362 Ablynx shares, representing 10.07% of the current 61,076,074 outstanding Ablynx shares, an increase from a former position of 5.40% (August 2016).

Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contactAblynx:Dr Edwin MosesCEOt:   +32 (0)9 262 00 07m: +32 (0)473 39 50 68e:  edwin.moses@ablynx.com

Marieke VermeerschDirector IR & Corporate Communicationst:   +32 (0)9 262 00 82m: +32 (0)479 49 06 03 e:  marieke.vermeersch@ablynx.comFollow us on Twitter @AblynxABLX

Ablynx media/analyst relationsFTI Consulting:Julia Phillips, Brett Pollard, Mo Noonan, Matthew Mosst: +44 20 3727 1000e: ablynx@fticonsulting.com

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/ad9a9547-5742-4564-a5fe-aeb173704865